Previous close | 1.2000 |
Open | 1.2200 |
Bid | 1.1800 x 100 |
Ask | 1.2900 x 100 |
Day's range | 1.2001 - 1.2900 |
52-week range | 0.4700 - 7.4600 |
Volume | |
Avg. volume | 157,126 |
Market cap | 38.795M |
Beta (5Y monthly) | 0.88 |
PE ratio (TTM) | N/A |
EPS (TTM) | -1.2000 |
Earnings date | 07 May 2024 - 10 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 6.75 |
DURECT Corporation (Nasdaq: DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the treatment of serious and life-threatening conditions such as acute organ injury and cancer, today announced acceptance of a late-breaking oral presentation at the European Association for the Study of the Liver (EASL) Congress 2024 to take place June 5-8, 2024 in Milan, Italy. The presentation will discuss data from the Company's Phase 2b AHFIRM trial, whi
DURECT Corporation (NASDAQ:DRRX) Q4 2023 Earnings Call Transcript March 27, 2024 DURECT Corporation beats earnings expectations. Reported EPS is $-0.27, expectations were $-0.36. DRRX isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Greetings and welcome to the DURECT Corporation Full […]
DURECT (DRRX) delivered earnings and revenue surprises of 25% and 1.19%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?